No description
-
2015 (v1)PublicationUploaded on: April 14, 2023
-
2018 (v1)Publication
Background and Aims. By means of 24 h impedance-pH monitoring, we aimed to evaluate the effect of two different meals with a bromatological balanced composition: one with a prevailing component of animal proteins and the other with vegetable proteins. Patients and Methods. We enrolled 165 patients with heartburn and negative endoscopy, who...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Esophageal complications caused by gastroesophageal reflux disease (GERD) include reflux esophagitis and Barrett's esophagus (BE). BE is a premalignant condition with an increased risk of developing esophageal adenocarcinoma (EAC). The carcinogenic sequence may progress through several steps, from normal esophageal mucosa through BE to EAC. A...
Uploaded on: March 27, 2023 -
2022 (v1)Publication
Therapeutic drug monitoring is a useful clinical decision aid in managing patients with inflammatory bowel disease treated with anti-tumor necrosis factor (anti-TNF). Various techniques are available to evaluate drug trough levels, and among these a point-of-care (POC) method has been proposed to overcome the limitations inherent to other...
Uploaded on: March 27, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Gastroesophageal reflux disease (GERD) is a common disorder of the gastrointestinal tract. In the last few decades, new technologies have evolved and have been applied to the functional study of the esophagus, allowing for the improvement of our knowledge of the pathophysiology of GERD. High-resolution manometry (HRM) permits greater...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Introduction: Crohn's disease (CD) is an inflammatory bowel disease of unknown etiology. However, increasing evidence suggests Mycobacterium avium subspecies paratuberculosis (MAP) as a putative causative agent: 1) MAP is the etiological agent of Johne's disease, a granulomatous enteritis affecting ruminants, which shares clinical and...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospectively analyzed data collected from 55...
Uploaded on: February 14, 2024 -
2019 (v1)Publication
Background: Ulcerative colitis is a chronic relapsing disease usually treated with mesalamine. The need of steroid therapy at diagnosis is generally considered as a poor prognostic factor. Aims: The aim of our study was to assess whether patients treated with corticosteroids at diagnosis have more clinical relapses, disease progression, or an...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Background: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lacking. We aimed to compare the effectiveness and tolerability between adalimumab originator,...
Uploaded on: January 13, 2024 -
October 2020 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023